Get the Stockscreener App
6.97
4.34%
0.29
After Hours:
7.30
0.33
+4.73%
Neuropace Inc stock is traded at $6.97, with a volume of 37,691.
It is up +4.34% in the last 24 hours and down -11.99% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
See More
Previous Close:
$6.68
Open:
$6.61
24h Volume:
37,691
Relative Volume:
0.42
Market Cap:
$203.50M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-4.10
EPS:
-1.7
Net Cash Flow:
$-19.87M
1W Performance:
-3.46%
1M Performance:
-11.99%
6M Performance:
-47.20%
1Y Performance:
-28.37%
1-Day Range:
$6.44
$7.00
1-Week Range:
$6.36
$7.59
52-Week Range:
$5.75
$18.15
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth By Investing.com - Investing.com UK
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up - MSN
34,059 Shares in NeuroPace, Inc. (NASDAQ:NPCE) Acquired by Bank of New York Mellon Corp - Defense World
BCI and EEG Market Future Developments, Upcoming Trends, and Top-Vendor Landscape 2020 to 2032 Medtronic, Natus Medical, Nihon Kohden, NeuroPace Inc – Cauverynews - Cauverynews
National Bank of Canada (OTCMKTS:NTIOF) Hits New 1-Year High at $94.20 - Defense World
Understanding the Risks of Investing in Noble Corp Plc (NE) - Knox Daily
Nothing is Better Than New Found Gold Corp (NFGC) stock at the moment - SETE News
Avoro Capital Advisors LLC Makes New Investment in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Navratna PSU stock rises on Rs 1,261-crore order from health ministry - Business Today
One Point One Solutions shares gain as company expands healthcare verticalCheck details - MSN
NEPSE index up by 11.58 points - The Himalayan Times
Nb bancorp director buys $1,862 in company stock By Investing.com - Investing.com UK
Acadian Asset Management LLC Has $520,000 Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Nampo Cape 2024 attracts 45 894 visitors, 10 000 visitors more than last year’s - Farmers Review Africa
Nomic® Secures $42M in Oversubscribed Series B to Expand Access to Protein Profiling - Business Wire
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by State of New Jersey Common Pension Fund D - Defense World
Carlyle Group Revives IPO for Nouryon: Private Equity Giant Eyes Big Move in Specialty Chemicals - Share Price India News
BCI and EEG Market 2031 Growth Drivers along with Top Players- Nihon Kohden, Natus Medical, Medtronic, NeuroPace Inc, Mindmaze SA, Brai – news - meramandsaur.in
NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.00 Consensus Target Price from Analysts - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Vagus Nerve Stimulators Market Report, Size, Share & Outlook - openPR
NeuroPace makes two key leadership appointments - Medical Buyer
Microelectronic Medical Implants Market Report 2024-2029, with Profiles of Leading Players, including Abbott, Biotronik, Cochlear, LivaNova, Medtronic, Neuropace and Nevro - Yahoo Finance UK
NeuroPace names new vice presidents for R&D and marketing - Investing.com
NeuroPace names new vice presidents for R&D and marketing - Investing.com India
NeuroPace Strengthens Management Team with Two Key Appointments - ForexTV.com
NeuroPace Strengthens Management Team with Two Key Appointments - StockTitan
Bioelectric Medicine Market Dazzling Worldwide | Major Giants Medtronic, Abbott, NeuroPace - Daily News Mirror
Neurostimulation Devices Market to Witness Huge Growth by 2031 - openPR
NeuroPace, Inc. (NASDAQ:NPCE) Shares Bought by Financial Advocates Investment Management - Defense World
NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences - StockTitan
NeuroPace to Participate in Upcoming Healthcare Conferences in September - StockTitan
NPCENeuroPace, Inc. Latest Stock News & Market Updates - StockTitan
NeuroPace: Only For Those With Strong Nerves (NASDAQ:NPCE) - Seeking Alpha
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up - Yahoo Finance
NeuroPace Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
FY2024 EPS Estimates for NeuroPace, Inc. (NASDAQ:NPCE) Increased by Analyst - MarketBeat
Research Analysts Set Expectations for NeuroPace, Inc.’s FY2024 Earnings (NASDAQ:NPCE) - Defense World
NeuroPace (NASDAQ:NPCE) Price Target Cut to $15.00 by Analysts at Wells Fargo & Company - Defense World
Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) Price Target at $14.00 - MarketBeat
NeuroPace’s (NPCE) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Position Raised by Vanguard Group Inc. - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Shares Purchased by Vanguard Group Inc. - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Leerink Partnrs Research Analysts Boost Earnings Estimates for NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Q3 2024 Earnings Estimate for NeuroPace, Inc. (NASDAQ:NPCE) Issued By Leerink Partnrs - Defense World
Earnings Release: Here's Why Analysts Cut Their NeuroPace, Inc. (NASDAQ:NPCE) Price Target To US$14.57 - Yahoo Finance
Selling Buzz: NeuroPace Inc [NPCE] 10% Owner ORBIMED ADVISORS LLC sells 15,690 shares of the company - Knox Daily
NeuroPace Inc (NPCE) Stock: A Year of Market Fluctuations - The InvestChronicle
NeuroPace, Inc. (NASDAQ:NPCE) Q2 2024 Earnings Call Transcript - Insider Monkey
NeuroPace (NASDAQ:NPCE) Issues Earnings Results, Beats Estimates By $0.03 EPS - Defense World
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):